Sarah Cannon Research Institute Oncology Partners

Nashville, Tennessee 37203

11 studies enrolling now · 15 studies all time

What they study most

Adult Disease, Adult Solid Tumor, Advanced Cancer, Advanced NRAS-Mutant Melanoma, Advanced NRAS-Mutant Solid Tumors, Advanced Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor, Advanced Solid Tumors, Biliary Tract Cancer, Cancer, EGFR, Esophageal Adenocarcinoma

Studies at this site

• A Phase 1 Study of IM-1021 in Participants With Advanced Cancer — Recruiting now
• Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer — Recruiting now
• AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors — Recruiting now
• A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma — Recruiting now
• Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations — Recruiting now
• A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer — Recruiting now
• Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors — Recruiting now
• A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer — Recruiting now
• A First-in-human Study of RLY-8161 in Advanced NRAS-Mutant Solid Tumors — Recruiting now
• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK201 in Participants With Advanced Solid Tumors — Recruiting now
• FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations — Recruiting now
• Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors — Running, not enrolling
• A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects With Advanced Solid Tumors — Completed
• A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) — Running, not enrolling
• A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7 — Paused